Crinetics climbs after reporting over $5 mln in Q4 net product revenue from recently launched drug
ReutersJan 5, 2026 2:20 PM
Shares of Crinetics Pharmaceuticals CRNX.O up 19.8% at $56.01 premarket after reporting over $5 million in Q4 preliminary 2025 net product rev from recently launched Palsonify
Palsonify approved in September 2025 for treating acromegaly, showing strong early sales and broad doctor adoption
Company also reports positive Phase 2 study of atumelnant, an experimental oral drug aiming to treat rare hormone disorders by blocking a hormone receptor to balance hormone levels
CEO Scott Struthers highlights broad prescriber base, favorable payer coverage, and over 200 enrollment forms in first three months post-approval
CRNX stock up 0.39% this year after dropping 9% in 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
National Debt Bomb Ignited? Musk Warns U.S. Will Be 1000% Bankrupt Without AI
TradingKey - Tesla (TSLA) CEO Elon Musk recently issued another warning regarding the rapidly ballooning U.S. national debt. He stated clearly that without artificial intelligence and robotics, the United States will inevitably head toward fiscal bankruptcy.TradingKey
6 hours ago
Why Sanae Takaichi Winning Japan’s Diet Election Led to a Surge in Japanese Stock Indices？
TradingKey - Reports indicate that the ruling coalition led by Japanese Prime Minister Sanae Takaichi has secured a single-party majority in the parliamentary elections held on Sunday (February 8). Following the news, the yen weakened slightly, while the Nikkei Index surpassed 57,000 for the first tTradingKey
7 hours ago
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 marketTradingKey
Wed, Feb 4
